The company published results from nine clinical trials of 900 patients that compared cumulative pain scores, opioid consumption and occurrence of opioid-related adverse events after administrating either EXPAREL or bupivacaine HCI.
EXPAREL also produced longer time to first opioid rescues and decreased opioid requirements and incidences of ORAEs. Thirty-six percent of bupivacaine HCI patients experienced at least one ORAE compared to 20 percent of EXPAREL patients.
More Articles on Anesthesia:
Nerve Blocks May Be Safer Than General Anesthesia
NorthBay Healthcare Purchases CASMED Brain Monitoring Device for Anesthesiologists
Study Shows Prior Use of Pain Relievers a Factor in Post-Operative Opioid Use
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
